0000950170-23-050807.txt : 20230929 0000950170-23-050807.hdr.sgml : 20230929 20230929163009 ACCESSION NUMBER: 0000950170-23-050807 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230927 FILED AS OF DATE: 20230929 DATE AS OF CHANGE: 20230929 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Buell Jennifer CENTRAL INDEX KEY: 0001711184 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 231296113 BUSINESS ADDRESS: BUSINESS PHONE: 781-674-4400 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 4 1 ownership.xml 4 X0508 4 2023-09-27 0001840229 MiNK Therapeutics, Inc. INKT 0001711184 Buell Jennifer 149 FIFTH AVENUE, SUITE 500 NEW YORK NY 10010 false true false false Chief Executive Officer false Common Stock 2023-09-27 4 M false 695750 A 1076465 D Restricted Stock Unit 2023-09-27 4 M false 695750 0 D Common Stock 0 695750 D Each restricted stock unit represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Represents restricted stock unit convertible into an equivalent number of shares of our common stock, which vested as to 100% of the underlying shares on September 27, 2023. By: /s/ Christine Klaskin, Attorney-in-Fact for Jennifer S. Buell 2023-09-27